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Cells with a genetic defect affecting a biological activity and/or a cell phenotype are generally called “cell mutants” and are a highly useful tool in
genetic, biochemical, as well as cell biological research. To investigate peroxisome biogenesis and human peroxisome biogenesis disorders, more
than a dozen complementation groups of Chinese hamster ovary (CHO) cell mutants defective in peroxisome assembly have been successfully
isolated and established as a model system.Moreover, successful PEX gene cloning studies by taking advantage of rapid functional complementation
assay of CHO cell mutants invaluably contributed to the accomplishment of isolation of pathogenic genes responsible for peroxisome biogenesis
diseases. Molecular mechanisms of peroxisome assembly are currently investigated by making use of such mammalian cell mutants.
© 2006 Elsevier B.V. All rights reserved.Keywords: CHO cell mutant; Genetic phenotype-complementation; Peroxin; Peroxisome ghost; Zellweger syndrome; Patients' fibroblast; Pathogenic gene1. Introduction
Mechanisms of peroxisome assembly, including peroxiso-
mal import of newly synthesized proteins, have been one of the
major foci in the peroxisome research. Studies on both
peroxisome biogenesis and peroxisome biogenesis disorders
(PBDs) at the molecular level rapidly progressed in the last
two decades. Many studies on cloning of genes, particularly
those of a very low level of expression, have benefited from
so-called functional cloning of genes, mostly cDNAs in mam-
malian cases, by phenotype complementation assay using cell
mutants deficient in biological pathways. The identification
and characterization of numerous essential genes, termed
PEXs encoding peroxisome assembly factors called peroxins,Abbreviations: CG, complementation group; CHO, Chinese hamster ovary;
IRD, infantile Refsum disease; NALD, neonatal adrenoleukodystrophy; PBD,
peroxisome biogenesis disorder; PTS, peroxisomal targeting signal; RCDP,
rhizomelic chondrodysplasia punctata; ts, temperature-sensitive; ZS, Zellweger
syndrome
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doi:10.1016/j.bbamcr.2006.09.012by means of the genetic phenotype-complementation of pero-
xisome assembly-defective cell mutants, named pex mutants
impaired in PEX genes, such as CHO cells (Table 1; see
below) [1,2], several yeast species including Saccharomyces
cerevisiae [3], Pichia pastoris [4,5], Hansenula polymorpha
[6], and Yarrowia lipolytica [7] (also see reviews [8–13]), and
plant Arabidopsis thaliana (see Nishimura et al. in this BBA
review issue) have made invaluable contributions to the study
of peroxisome biogenesis and protein trafficking in eukaryotes
[14,15]. We herein summarize mammalian model cell systems
in studying physiology, biogenesis, and human disorders of
peroxisomes.
2. Genetic approaches to studying mammalian peroxisome
biogenesis
Mutually complementary approaches, i.e. the genetic pheno-
type-complementation of peroxisome assembly-defective
mutants of mammalian somatic cells such as CHO cells and a
combination of the human orthologue isolation by homology
search on the human expressed sequence tag database using
yeast PEX genes and cells derived from PBD patients, have been
taken for investigation of peroxisome biogenesis and the
molecular defects of the patients with PBDs of more than a
Table 1
Complementation groups and complementing genes of peroxisome deficiencies
PBD patients Phenotype CHO mutants Gene Peroxisome ghosts Peroxin
Japan USA/EU (kDa)
E 1 ZS, NALD*, IRD* Z24, ZP107 PEX1 + 143 AAA family
F 10 ZS, IRD* Z65 PEX2 (PAF1) + 35 PMP, RING
G 12 ZS ZPG208 PEX3 − 42 PMP
2 ZS, NALD ZP105*, ZP139 PEX5 + 68 PTS1 receptor, TPR family
C 4 (6) ZS, NALD* ZP92 PEX6 + 104 AAA family
R 11 RCDP ZPG207 PEX7 + 36 PTS2 receptor, WD motif
B 7 (5) ZS, NALD PEX10 + 37 PMP, RING
3 ZS, NALD, IRD ZP109 PEX12 + 40 PMP, RING
H 13 ZS, NALD* ZP128 PEX13 + 44 PMP, PTS1-DP, SH3
K 15 ZS ZP110 PEX14 + 41 PMP, PTS-DP, PTS2-DP
D 9 ZS PEX16 − 39 PMP
J 14 ZS ZP119 PEX19 − 33 CAAX motif
A 8 ZS, NALD*, IRD* ZP124, ZP167 PEX26 + 34 PMP, Pex1p–Pex6p recruiter
ZP114 +
ZP126 +
ZS, Zellweger syndrome; NALD, neonatal adrenoleukodystrophy; IRD, infantile Refsum disease.
RCDP, rhizomelic chondrodysplasia punctata; *, temperature sensitive phenotype; PMP, peroxisome membrane protein; TPR, tetratricopeptide repeat.
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(Table 1; see below) [1,2,16–18].
2.1. Peroxisome-deficient mammalian cell mutants
2.1.1. Cell mutants lacking peroxisomes
2.1.1.1. Cell lines from patients with PBDs. The PBDs
include Zellweger syndrome (ZS), neonatal adrenoleukodystro-
phy (NALD), infantile Refsum disease (IRD), and rhizomelic
chondrodysplasia punctata (RCDP) [19] (see also Steinberg et
al. in this issue). Patients with ZS show severe neurological
abnormalities, characteristic dysmorphism and hepatomegaly,
and rarely survive with an average life of only 6 months. NALD
patients have the symptoms similar to ZS patients, but they
survive a little longer, early childhood. In contrast, patients with
IRD do not manifest significant abnormalities in the central
nervous system, and survive with the longest average life, 3–
11 years [19]. RCDP patients show distinct phenotypic charac-
teristics such as severe growth failure and rhizomelia. Genetic
heterogeneity consisting of 12 CGs has been identified in PBDs
by cell-fusion CG analysis using fibroblast cell lines derived
from PBDpatients [2,16,20,21] (Table 1). A novel CG, CG15, of
ZS was very recently identified [22], hence indicative of totally
13 genotypes of PBDs. The primary cause for PBDs was
revealed to be the impaired biogenesis of peroxisomes [2,16].
Fibroblasts from patients with less severe NALD and milder
IRD, but not from those with ZS, show a temperature-sensitive
(ts) phenotype, where the impaired protein import is restored in
cell culture at 30 °C, but not at normal 37 °C [23–30]. Such
cellular phenotype implicates the clinical severity between ZS,
NALD, and IRD [24,28].
2.1.1.2. Isolation of CHO cell lines. Two methods were
developed for the isolation of mammalian somatic cell mutants
defective in peroxisome biogenesis: (i) colony autoradiographicscreening with a phenotypic marker, dihydroxyacetonepho-
sphate acyltransferase (DHAP-ATase) deficiency [31,32]; and
(ii) the photo-sensitized selection method using 9-(1′-pyrene)
nonanol (P9OH) and an exposure to longwave-length ultraviolet
(UV) light which kills wild-type cells incorporating P9OH as a
fatty alcohol into plasmalogens and survive cell mutants defi-
cient in such activity [33,34]. By the colony autoradiographic
screening, CHO cell mutants, ZR78 and ZP82, of a single CG
were isolated [35]. We likewise isolated two distinct CGs of
CHO mutants, Z24 and Z65, defective in matrix protein import
[32] (Fig. 1b). ZR78 and ZR82were later classified into the same
CG as Z65 [36]. Then, by the photo-sensitized selection method
isolated were 13 CGs of peroxisome-deficient CHO cell mu-
tants, including ones of the same CGs isolated by the screening
method [2,37,38]: ZP107 [39], ZPG208 [38], ZP105/ZP139
[39,40], ZP92 [34], ZPG207 [38], ZP109 [39], ZP128 [41],
ZP110 [42], ZP119 [37], ZP124/ZP167 [43], ZP114 [42], and
ZP126 [43] (Table 1). All of CHO cell mutants showed a typical
phenotype of deficiency in peroxisome biogenesis, such as the
impaired protein import, no catalase latency, severely affected
DHAP-ATase activity, as noted in fibroblasts from PBD patients
[2,32,34,38,39,42,43]. Peroxisomal remnants, called membrane
ghosts, are seen in most of the CHO mutants [1,2] (Fig. 1f),
except for ZP119 [37] (Fig. 1c and g) and ZPG208 [38], both
devoid of peroxisomal ghosts as reported for fibroblasts from
peroxisome-deficient PBD patients [44–47].
A complete set of CG analyses by cell-fusion between 13
CGs of CHO cell mutants and 12 CGs of fibroblasts from pa-
tients with PBDs revealed that 10 CGs of CHO mutants repre-
sent the human PBD CGs (Table 1) [20,34,37,38,41,43,48].
ZP110 was recently classified as the same CG as the newly
identified CG15 of a PBD patient [22] (Table 1). CHO mutants,
ZP114 and ZP126, were different from any of the 13 human
CGs, indicating that genetic heterogeneity comprising 15
complementation groups (CGs) has been identified in mammals.
Accordingly, peroxisome assembly apparently requires at least
Fig. 1. Morphology of CHO cell mutants defective in peroxisome biogenesis. Cells are stained with antibodies to PTS1 (a–d), PMP70 (e–g), and Pex14p (h). Cells are
as indicated at the top. Scale bar, 20 μm (a–c and e–g); 10 μm (d and h). In contrast to the wild-type CHO-K1 cells, PTS1 proteins are discernible in the cytosol in Z65
and ZP119. Z65 contains PMP70-positive peroxisomal remnants, whilst ZP119 is absent from such peroxisome ghosts, indicative of the defect of membrane protein
import. In ZP121, abnormal morphology of peroxisomes is evident, despite of import of membrane and matrix proteins.
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with ts-phenotypes including ZP105 of CG2 [49], ZPEG309 of
CG10 [50], and ZPEG252 of CG1 [51] were also isolated.
2.1.2. Mutants defective in enzymes involved in plasmalogen
synthesis
The first and second steps of the synthesis of plasmalogens,
ether glycerolipids, are catalyzed by peroxisomal enzymes,
DHAP-ATase and alkyl-DHAP synthetase [52]. Deficiency of
DHAP-ATase and alkyl-DHAP synthetase is responsible for
RCDP types 2 and 3, respectively, of PBDs [53,54].
CHO cell lines with deficiency in the synthesis of plasmalo-
gens were isolated using the P9OH/UV method by Zoeller and
his colleagues, including the mutants each impaired in DHAP-
ATase [55] and alkyl-DHAP synthetase [56]. These two cell
lines and another CHO mutant defective in acyl/alkyl-DHAP
reductase [57] are powerful tools for the study of plasmalogen
physiology.
2.1.3. Mutants showing abnormal peroxisome morphology
A CHO mutant ZP121 showing morphologically abnormal
peroxisomes and apparent dysmorphogenesis of mitochondria
was isolated by the P9OH/UV selection method [43]. ZP121
contains peroxisomes with aberrant morphology, fiber-like
structures as stained with antibody to the membrane peroxin,
Pex14p (Fig. 1h). Unlike typical, matrix protein import-de-
fective mutants such as Z65 (Fig. 1b), ZP121 imports pero-
xisomal matrix proteins including those with PTS1 (Fig. 1d) and
PTS2-type 3-ketoacyl-CoA thiolase. ZP121 shows a ts pheno-
type, where the morphology of peroxisomes and mitochondria
becomes normal at 40 °C [58]. Furthermore, ZP121 is lowered in
the level of phospholipids, plasmalogens and phosphatidyletha-
nolamine, and is less sensitive to oxidative stresses [58], thus
explaining its resistance to the P9OH/UV selection.
Dynamin-like protein 1 gene,DLP1, was very recently found
to be responsible for the phenotype of ZP121, where an inacti-
vating point-mutation G363D in 699-amino-acid long DLP1
was the cause of the mutant's abnormalities [58]. The G363D
mutation severely affected the GTPase activity of DLP1. Thus,
ZP121 is the first mammalian dlp1 mutant cell line and is a
useful tool for studying peroxisome morphogenesis.2.2. Genes required for peroxisome biogenesis
2.2.1. Genetic phenotype-complementation assay
Forward genetics using animal somatic cell mutants is a
powerful approach for isolating essential genes such as the
peroxin genes, PEXs.
PEX2 (peroxisome assembly factor-1): We searched for the
gene encoding a factor complementing the defects of one of the
CHO cell mutants, Z65, by transfecting a rat liver cDNA library
[59]. Transfectants were selected by the 12-(1′-pyrene) dodeca-
noic acid (P12)/UV method [60], containing peroxisomes as
assessed by immunofluorescence microscopy using anti-cata-
lase antibody. An open reading frame encoded a novel 35-kDa
protein of 305 amino acids, termed peroxisome assembly factor-
1 (PAF-1) [59] (Table 1; Fig. 2A). PAF-1was unified as PEX2 in
1996 [61]. Pex2p is a peroxisomal integral membrane protein
with two membrane-spanning segments and a RING finger
motif, C3HC4 [62]. Pex2p apparently functions as a component
of the transmembrane import machinery of newly synthesized
proteins. In mammals, rat, human, Chinese hamster, and mouse
PEX2s have been isolated [36,59,63–65].
PEX6: Rat PAF-2 (PEX6) was cloned by the functional
complementation of another CHO mutant, ZP92, using an effi-
cient, transient cDNA library-transfection system [66] (Table 1).
The morphological and biochemical abnormalities of ZP92
caused by an impaired peroxisome assembly were restored by
PEX6 expression. Rat Pex6p is 978-amino acid-long 104-kDa
protein and contains two Walker motifs of the AAA family
(ATPases associated with diverse cellular activities) of ATPases
[67], where B1 site is not conserved. Human Pex6p cDNA en-
codes a protein of 980 amino acids with 87% identity to rat
Pex6p [68]. Pex6p is associated with peroxisomes [66,69–71].
Seven more peroxin cDNAs, PEX1, PEX3, PEX5, PEX12,
PEX13, PEX14, and PEX19, were likewise cloned by func-
tional phenotype-complementation assay on CHO cell mutants,
ZP107, ZPG208, ZP105, ZP109, ZP128, ZP110, and ZP119,
respectively [40,41,72–77] (Table 1). Human PEX5 [78] [79],
PEX14 [80], and PEX19 (PXF) [81] were earlier identified.
More recently, PEX26 was isolated after a long-term search
by the same approach using CHO ZP167 cells [70] (Table 1;
Fig. 2B).
Fig. 2. Cloning of pathogenic genes of PBDs. Peroxisome-restoring PEX genes
were isolated by functional complementation assay using CHO mutants. (A)
Restoration of peroxisomes in Z65 (a) by transfection of rat liver cDNA library
(b). Transformed cells positive in catalase import contained PAF-1 (PEX2). In
fibroblasts from a patient with ZS of CG10 (c), expression of PAF-1 restored the
impaired import of catalase (d). Scale bar, 20 μm (a and b); 30 μm (c and d). (B)
CG8 CHO mutant ZP167 (a) was complemented in EGFP-PTS1 import upon
transfection of a subpool containing PEX26 of human kidney cDNA library (b).
PEX26 expression in fibroblasts (c) from a NALD patient of CG8 restored the
catalase import (d). Scale bar, 20 μm (a); 30 μm (b).
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An alternative strategy, i.e. the homology search by screen-
ing the expressed sequence tag database using yeast PEX genes,
has successfully led to isolation of human orthologue genes:
PEX1 [82,83], PEX3 [84], PEX5 [85], PEX6 [69], PEX7 [86–
88], PEX10 [89,90], PEX12 [91], PEX13 [92], PEX14 [93],
and PEX16 [94,95].
2.3. Pathogenic genes of peroxisome-deficient diseases
The search for the pathogenic genes of PBDs was one of the
major foci in recent studies on peroxisome biogenesis using
mutants of mammalian cell lines and yeasts.
PEX2 (Zellweger gene) deficiency: To elucidate the genetic
cause of a PBD, human PEX2 cDNA was transfected to
fibroblasts from a ZS patient of CG10, the same CG as the CHO
mutant Z65 (Fig. 2A, c and d) [63]. The impaired peroxisome
biogenesis as well as deficiency of metabolic enzyme activities
such as DHAP-ATase and β-oxidation of very-long-chain fatty
acids was complemented, thereby indicating the primary defect
of this patient to be a dysfunction of Pex2p. This patient con-
tained a homozygous nonsense point mutation at a CpG
dinucleotide, i.e. in a codon CGA for at 119Arg, in PEX2, thus
resulting in the creation of a premature termination (TGA) [63].Collectively, for the first time we were able to identify the
primary defect causing human PBD, ZS. Several patients of this
CG have been analyzed: homozygote for mutation at Arg119Ter
[96,97] and heterozygote for mutation at Arg119Ter and
Arg125Ter [98].
Other PEXs, including PEX1, PEX3, PEX5, PEX6, PEX7,
PEX10, PEX12, PEX13, PEX14, PEX16, PEX19, and PEX26,
that had been cloned by the functional complementation assays
using CHO mutants and/or the expressed sequence tag homo-
logy search were shown to be responsible for PBDs of 12 distinct
CGs [2,18,22,28,70,99] (Table 1). Isolation of PEX26 made it
possible to clone the 12th, latest pathogenic gene responsible for
PBDs of CG8 sought for more than a decade (Fig. 2B, c and d)
[28,70].
3. Biogenesis of peroxisomes
3.1. Lessons from mammalian mutant cell lines
Of many benefits from mammalian cell mutants in studies of
peroxisome biogenesis and pathogenic defects of PBDs, two
findings learned from the mutants with distinct genotype and
phenotype relationship are addressed here (Fig. 3).
3.1.1. Two isoforms of Pex5p
Two phenotypically distinct groups of PEX5-defective CHO
cell mutants of CG2 were isolated [40]. One group of the pex5
CHO mutants such as ZP105 showed the import defect of both
PTS1- and PTS2-proteins, whilst another group represented by
ZP139 was impaired in transport of PTS1-proteins but not of
PTS2-proteins, exactly as in yeast pex5 mutants. Fibroblasts
with such distinct phenotypes from patients of CG2 were also
identified [85,100]. The import of both PTS1- and PTS2-
proteins was defective in one ZS patient analyzed, while only
the transport of PTS1-proteins was apparently impaired in the
second NALD patient [85]. In mammals, including the Chinese
hamster and humans, two isoforms of Pex5p termed Pex5pS
and Pex5pL with an internal 37-amino-acid insertion were
identified [40,100], whilst in yeast only a single type of Pex5p
was isolated [8,101]. Pex5pS and Pex5pL form a homomeric as
well as heteromeric dimer [49], tetramer [102], or exist as a
monomeric form [103]. Expression of either type of Pex5p
complemented the impaired PTS1 import in CHO pex5 mutants
as in yeast, but only Pex5pL could rescue the PTS2-import
defect noted in ZP105 [40]. Likewise, only Pex5pL can restore
PTS2 import in fibroblasts from a CG2 patient with ZS [100].
Pex5pL directly interacts with the PTS2 receptor, Pex7p,
carrying its cargo PTS2-protein in the cytosol [49,104–106].
Pex5pL, but not Pex5pS, translocates the Pex7p–PTS2–protein
complexes to peroxisomes. Furthermore, another pex5 mutant
cell line, ZPG231, showed a novel phenotype, PEX5-defective
but impaired solely in PTS2 import [104]. Missense point
mutation, Ser214Phe, in PEX5 disrupted interaction of Pex5pL
with Pex7p–PTS2 complexes, resulting in complete elimination
of the PTS2 import pathway. Therefore, Pex5pL plays an
exclusively pivotal role in PTS2 transport, in addition to PTS1
import.
Fig. 3. A schematic view of peroxisome biogenesis in mammals. The intracellular location and molecular properties of peroxins so far identified are shown. Peroxins
are divided into three groups: (i) peroxins that are required for matrix protein import; (ii) those including Pex3p, Pex16p, and Pex19p, responsible for peroxisome
membrane assembly; (iii) those such as Pex11p apparently involved in proliferation. DLP1 and Fis1 are also involved in peroxisome morphogenesis. Peroxins and
DLP1 shown in whitened letters indicate that CHO cell mutants deficient in respective peroxins are isolated (see text).
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Fibroblasts from patients with less severe NALD and milder
IRD, but not from those with the most severe ZS, show a ts
phenotype, where the impaired import of matrix proteins such as
catalase is restored in cell culture at 30 °C, but not at normal 37 °C
[23–30]. Expression of the responsible pathogenicPEXmutations
derived from PBD patients in respective CG pexmutants of CHO
cells, such as PEX26 variants in pex26 ZP167 [28,107], results in
cell phenotypes similar or identical to those in the human cell
lines. These findings confirm that the degree of ts in pex cell lines
is predictive of the clinical phenotype in patients with respective
PEX gene deficiency, inversely implicating the clinical severity
between ZS, NALD, and IRD [24,28].
3.2. Membrane assembly
Three mammalian peroxins, Pex3p, Pex16p, and Pex19p,
have been isolated by the functional phenotype-complementa-
tion assay on CHO cell mutants [73,77] and the expressed
sequence tag database search using yeast PEX genes
[81,84,94,95] and were shown to be essential for peroxisome
membrane assembly. Mechanistic insights on membrane
biogenesis are addressed in Section 3.2. Biogenesis of Pero-
xisomal Membranes of this BBA issue.
4. Perspective
More than 15 CGs of mammalian cell mutants deficient in
peroxisome biogenesis including three CGs defective of mem-brane assembly have been identified, including PBD patients'
fibroblasts and CHO mutant cell lines (Table 1; Fig. 3).
Pathogenic genes are now elucidated for all of PBD CGs.
Biochemical functions of only several peroxins involved in the
import of matrix proteins have been better elucidated. Molecular
mechanisms of membrane assembly are also currently being
challenged. Investigations using the cloned peroxins and pex
mutants including CHO mutants and those from PBD patients
will shed light on the mechanisms involved in peroxisome
biogenesis and pathogenesis of PBDs.
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